Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Pharmaceuticals Inc.

www.regeneron.com

Latest From Regeneron Pharmaceuticals Inc.

Drug/Device Combinations: Shock For Pharma As It Seeks Notified Body Resources Too

With the delivery of drugs via medical devices commonplace now, and the introduction of new EU rules for these products via the MDR, the pharma industry is also searching for notified body capacity. It is dismayed at the uncertainty ahead.

Europe Medical Device

Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Pfizer's Abrocitinib Looks Competitive In Atopic Dermatitis

The first detailed Phase III results for the company's next-generation oral JAK inhibitor abrocitinib appear to show efficacy on par or better than data from Sanofi/Regeneron's Dupixent and may give Lilly's Olumiant a run for its money in AD.

Clinical Trials Research and Development Strategies

Finance Watch: 3Q Biopharma Venture Capital Financings Fell From 2Q Spike

VC deals totaled $8.3bn in the first half of 2019, but the year's total rose to just $11.5bn at the end of September, reflecting only a $3.2bn third quarter gain. Among recent financings, Cygnal emerged from stealth mode with $65m invested to date.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Regeneron Pharmaceuticals Inc.
  • Senior Management
  • Leonard S Schleifer, MD, PhD, Pres. & CEO
    Robert E Landry, SVP, Fin. & CFO
    George D Yancopoulos, MD, PhD, Pres. & CSO
  • Contact Info
  • Regeneron Pharmaceuticals Inc.
    Phone: (914) 847-7000
    777 Old Saw Mill River Rd.
    Tarrytown, NY 10591
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register